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Euclea natalensis A.DC., Knowltonia vesicatoria (L.f) Sims, and Pelargonium sidoides DC. are South African plants traditionally
used to treat tuberculosis. Extracts from these plants were used in combination with isoniazid (INH) to investigate the possibility
of synergy with respect to antimycobacterial activity. The ethanol extract of K. vesicatoria was subjected to fractionation to identify
the active compounds. The activity of the Knowltonia extract remained superior to the fractions with a minimum inhibitory
concentration (MIC) of 625.0μg/mL against Mycobacterium smegmatis and an MIC of 50.00μg/mL against M. tuberculosis.
The K. vesicatoria extract was tested against two diﬀerent drug-resistant strains of M. tuberculosis, which resulted in an MIC of
50.00μg/mL on both strains. The combination of K. vesicatoria with INH exhibited the best synergistic antimycobacterial activity
with a fractional inhibitory concentration index of 0.25 (a combined concentration of 6.28μg/mL). A ﬁfty percent inhibitory
concentration of this combination against U937 cells was 121.0μg/mL. Two compounds, stigmasta-5,23-dien-3-ol (1) and 5-
(hydroxymethyl)furan-2(5H)-one (2), were isolated from K. vesicatoria as the ﬁrst report of isolation for both compounds from
this plant and the ﬁrst report of antimycobacterial activity. Compound (1) was active against drug-sensitive M. tuberculosis with
an MIC of 50.00μg/mL.
1.Introduction
For the last 40 years there has been little progress in the
treatment of Tuberculosis (TB). The standard albeit dated
treatmentregimeisstrictandlengthy(6–9months)resulting
in adverse side eﬀects and inevitable patient noncompliance.
It is no surprise that the emergence of multiple and exten-
sively drug resistant strains of Mycobacterium tuberculosis
(M. tb) is on the rise. The WHO recently reported that in
some areas of the world, one in four people with TB becomes
ill with a form of the disease that can no longer be treated
with standard drugs [1]. In addition, HIV/AIDS increases
the risk for developing active TB and renders TB diﬃcult
to diagnose and treat. The TB-HIV/AIDS coinfection rate
in South Africa is distressingly high, with an estimated
73 percent of new TB patients coinfected with HIV [2].
The search for new TB treatments that are eﬀective against
resistant strains of M. tb and treatments which can augment
the potential of existing drugs against the disease is more
important today than at any other time in history. Without
the introduction of new treatments, TB patients will run out
of options for eﬀective drugs.
Plant products have received considerable attention as
potential anti-TB agents with a recent review emphasizing
plant products as sources of antimycobacterial extracts and
compounds [3]. Most traditionally used plant therapies rely
for their eﬀects on a variety of compounds and synergy
between these compounds, however, there are numerous
beneﬁts for isolating and identifying active constituents from
these bioactive plants. These beneﬁts include characterising
toxicity proﬁles, simpler determination of modes of action,
and new activities of known compound which adds to
the wealth of information on phytochemicals. Combining
plant extracts and current TB drugs holds advantages
such as decreased toxicity proﬁles, increased bioavailability2 Evidence-Based Complementary and Alternative Medicine
and activity, and reduced onset of microbial resistance.
Testing isolated compounds from plant extracts, using whole
extracts alone, and in combination with other extracts and
current anti-TB drugs, covers a wider range for activity and
possible treatment therapies. In this study the synergistic
antimycobacterial activity of three South African plants as
wellastheircytotoxicityandtheisolation,identiﬁcation,and
antimycobacterial activity of compounds obtained from the
ethanol (EtOH) extract of Knowltonia vesicatoria is reported.
In previous experiments, the EtOH extract of K. vesi-
catoria (aerial parts) was found to be active against both
Mycobacterium smegmatis and M. tuberculosis [4]. Knowlto-
nia vesicatoria (Ranunculaceae) is relatively new to the ﬁeld
of tuberculosis research, and in general very little work has
been done on this speciﬁc plant, even though traditional
uses related to TB have been documented [5]. Recently
the genus Knowltonia has been subsumed within the genus
Anemone, and K. vesicatoria is now known as Anemone
vesicatoria (L.f) Prantl [6]. To avoid confusion the name
Knowltonia vesicatoria has been retained throughout the
paper. One of the objectives of the study was to identify the
antimycobacterial compounds present in the K. vesicatoria
extract and to eliminate the possibility of tannins as the
antimycobacterial actives. In addition, extracts prepared
from two well-known South African plants, Pelargonium
sidoides DC. (root, EtOH) and Euclea natalensis A.DC.
(root, chloroform (CHCl3)) were included in the study to
investigate the possibility of synergistic antimycobacterial
action when combined with each other, K. vesicatoria,a n d
the ﬁrst-line antitubercular drug, isoniazid (INH).
Pelargonium species (Geraniaceae) are highly valued by
traditional healers for their curative properties and are
wellknown for treatment of coughs, diarrhoea, and tuber-
culosis. A review by Brendler and van Wyk [7] discusses all
aspects of Pelargonium sidoides, including a complete and
comprehensive take on the anti-TB, antibacterial, antifungal
and immunomodulating activity of this valuable plant.
The roots of Euclea species (Ebenaceae) are used in
southern African traditional medicinal preparations to treat
chest complaints, chronic asthma, leprosy, and infections,
among other ailments [8–11]. Euclea natalensis is a familiar
plant to TB research and the antimycobacterial activity
against M. tb by extracts and compounds of Euclea natalensis
roots has been previously reported [12], including the
synergistic activity of this extract with INH [13].
2.MaterialsandMethods
2.1. Plant Material. Knowltonia vesicatoria syn Anemone
vesicatoria was procured in the province of Gauteng, South
Africa. The stems and leaves (aerial parts) were collected
during January. Previously, roots of P. sidoides were collected
from the Free State province, and roots from E. natalensis
werecollectedfromKwaZulu-NatalprovinceofSouthAfrica.
A voucher specimen (PRU 096449, P 092559 and N.L.
22, resp.) for each plant was deposited and identiﬁed at
the H.G.W.J. Schweickerdt Herbarium (PRU), University of
Pretoria, South Africa.
2.2. Microorganisms and Cell Lines. Mycobacterium smeg-
matis (MC2 155) cultures, obtained from, American Type
Culture Collection (ATCC), Culture Collection (ATCC),
MD, USA were kindly donated from the Medical Research
Council (MRC) in Pretoria, South Africa. The cultures were
kept on Middlebrook 7H11 agar (Sigma-Aldrich Chemical
Co., South Africa) and stored at approximately 8◦C, for no
longer than one month. Several aliquots of the prepared
mycobacterial cultures in Middlebrook 7H9 broth (Sigma-
Aldrich Chemical Co., South Africa) were frozen in cryovials
at −70◦C.
Three M. tb strains were used in the experimental
procedures, which were carried out at the Medical Research
Council (MRC), Pretoria, South Africa. H37Rv (ATCC
27294), a drug-susceptible strain of M. tb,s e n s i t i v et o
the ﬁrst-line antituberculous drugs, INH, rifampicin (RIF),
ethambutol (EMB), and streptomycin (STR), was obtained
from the ATCC. Mycobacteriumtuberculosiswere plated onto
slants of L¨ owenstein-Jensen (LJ) medium and allowed to
grow for 3-4 weeks at 37◦C. Two clinical drug resistant
strains, 4388 (resistant to INH and EMB) and 5497 (resistant
to RIF, INH, EMB, STR) were maintained in BACTEC 12B
medium (7H12 medium containing 14C-labeled substrate,
palmitic acid) at 37◦C until a growth index (GI) of 400 was
reached. Both resistant strains were obtained from an MRC
proﬁciency test (round 14) from Belgium. These resistant
strains were only used to test the activity of the K. vesicatoria
(EtOH) extract.
The histiocytic lymphoma cell line, U937, was obtained
from Highveld Biological (Pty) (Ltd.) (Sandringham, South
Africa) and maintained in complete RPMI 1640 medium
(pH 7.2) (Sigma-Aldrich Chemical Co., South Africa),
supplemented with 10% heat-inactivated foetal calf serum
(FCS),2mML-glutamine,anda0.1%antimicrobialsolution
(pennicilin, streptomycin, and an antifungal. fungizone).
2.3. Extraction and Isolation. Prepared extracts of Euclea
natalensis (CHCl3)a n dPelargonium sidoides (EtOH) were
kindly donated by Professor N. Lall. The collected aerial
parts of K. vesicatoria were allowed to air-dry in open
sample bags away from direct sunlight. The dried plant
material (530.0g) was extracted with 2.50L of 100% EtOH.
T h es o l v e n ta n dp l a n tm a t e r i a lw a sp l a c e do na ne l e c t r i c
shaker and vigorously shaken by hand twice a day for
seven days. Each day the plant material were ﬁltered, the
extract concentrated under reduced pressure with a rotary
evaporator, and clean EtOH was added to the remaining
plant material. A total yield of 148.4g of dried extract was
obtained (28% of the total dried plant material). Sixty grams
of the K. vesicatoria EtOH extract was subjected to a solvent
partitioning method for the removal of polyphenolics [14].
The dried EtOH extract was dissolved in 1.5L of a 9:1
EtOH:dH2O solution which was then partitioned with an
equal volume of hexane. The hexane layer was concentrated
under reduced pressure and stored for further testing of the
nonpolar components (2.35g). A portion of the 90% EtOH
layer was concentrated under reduced pressure and stored
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(750mL) was partitioned with equal volumes of CHCl3 :
methanole (MeOH) (4:1) and water. The two layers were
then separated. The EtOH layer was concentrated under
reduced pressure and stored (13.27g). The chloroformic
layer was then washed with an equal volume (750mL) of 1%
w/v NaCl in water. The chloroformic layer was then dried
under reduced pressure, yielding 9.86g of polyphenol-free
extract.AllthelayerswerescreenedagainstM.smegmatisand
the active layers tested against M. tb.
The crude K. vesicatoria extract (28.00g) was subjected
to silica column chromatography (CC, size 10 × 23cm)
using hexane: ethyl acetate (EtOAc) mixtures of increasing
polarity (0 to 100%) followed by MeOH. Fractions (1–
26) of 500mL were collected. Similar fractions were pooled
together and dried, which resulted in nine main fractions.
These nine fractions were subjected to a TLC bioautographic
antibacterial assay using M. smegmatis.F r a c t i o n3( F 3 ,
404.0mg) was subjected to silica gel CC (size 3×25cm)
gradient elution from hexane to ethyl acetate (0 to 60%)
on the basis of its inhibitory activity on M. smegmatis, to
yield pure compound (1) (30.70mg, Figure 2). Fraction 8
(F8, 378.9mg) from the ﬁrst column contained very few
constituents with one main compound and was chosen for
further isolation with a silica gel CC (hexane-ethyl acetate,
30 to 100%). Fifty subfractions were obtained and pooled
t o g e t h e ra st w om a i nf r a c t i o n s( F 8 . 1a n dF 8 . 2 ) .F r a c t i o n
8.2 was further puriﬁed with a Sephadex column using
MeOH which resulted in the 3:2 isomer mixture of (2)
and its enantiomer (3) (123.3mg, Figure 2). The structural
identity of the mixture was elucidated by physical (mp. [α]D)
and spectroscopic (1Ha n d13C NMR) data and was also
subjected to 2D COSY, HMQC, HMBC and NOESY spectra.
The isomer mixture (30.00mg) was subjected to column
chromatography (CC, 3×30cm) using 150g of inactivated
silica (1.00mLdH2O for each 10.00g of silica) eluted with
hexane: EtOAc (40 to 60%). This procedure separated a
portion (8.00mg) of the main isomer (2) from the mixture.
Isolation of minor isomer (3) was unsuccessful.
2.4.AntimycobacterialActivityofSolventPartitionedFractions
on M. smegmatis Using Microplate Susceptibility Testing.
Cryopreserved or freshly scraped colonies were suspended in
fresh Middlebrook 7H9 broth (Sigma-Aldrich Chemical Co.,
South Africa) and incubated for 24h at 37◦C. The overnight
liquid culture was then transferred to a sterile test tube
containing 20–25 glass beads (with a 2.00mm diameter) and
homogenised by using a vortex mixer (Heidolph, Germany)
for 5–10min. The broth culture was then left still for 5–
10min to let larger clumps of mycobacteria settle. The
supernatant was carefully decanted to a sterile ﬂask and
adjusted with Middlebrook 7H9 broth base to an optical
density of 0.2 (log phase) at 550nm (Beckman DU-720
UV spectrophotometer), yielding 1.26 × 108 colony-forming
units per millilitre (CFU/mL). The microdilution test was
performed in 96-well microtiter plates as described earlier
[15, 16].
The plant extract and fractions were dissolved in 10%
dimethyl sulfoxide (DMSO) to obtain a stock concentration
of 10mg/mL. Ciproﬂoxacin (Sigma-Aldrich Chemical Co.,
South Africa) at ﬁnal concentrations ranging from 2.00 ×
10−3 to 7.80 × 10−5 mg/mL served as the positive drug
control [17].Serialtwofolddilutionsofeachtestsamplewere
made with Middlebrook 7H9 broth base (Sigma-Aldrich
Chemical Co., South Africa) to yield volumes of 100mL/well
with ﬁnal concentrations ranging from 2.50 to 0.08mg/mL.
Mycobacterium smegmatis (100mL adjusted to an optical
density value of 0.2 to ensure the bacteria suspension was
at the start of the log phase and approximately 1.26 ×
108 CFU/mL upon test commencement) was also added to
each well containing the samples and mixed thoroughly to
give a ﬁnal volume of 200mL/well. The solvent control,
DMSO at 12.50%, did not show inhibition on the growth
of the bacteria. Tests were done in triplicate on two diﬀerent
occasions.
The plates were sealed with paraﬁlm and incubated
at 37◦C for 24h. The minimum inhibitory concentration
(MIC) of samples was detected following addition (40μL) of
0.20mg/mL p-iodonitrotetrazolium chloride (INT, Sigma-
Aldrich Chemical Co., South Africa) to duplicates of each
sample triplicate and incubated at 37◦Cf o r3 0 m i n[ 16].
Viable bacteria reduced the yellow dye to a pink colour.
The MIC was deﬁned as the lowest sample concentration
thatpreventedthischangeandexhibitedcompleteinhibition
of bacterial growth. The minimal bactericidal concentration
(MBC) was determined by taking 50.0μL aliquots from the
remaining INT excluded wells to 150.0μLo f7 H 9b r o t hi na
fresh 96-well plate. This new plate was sealed with paraﬁlm
and incubated for 48h at 37◦C. The MBC was recorded as
the lowest concentration of sample which did not produce
the pink colour change after the addition of 40.0μLI N T
(0.20mg/mL).
2.5. Antitubercular Rapid Radiometric Assay Using M. tuber-
culosis. The radiometric respiratory techniques using the
BACTEC 460 system (Becton Dickinson Diagnostic Instru-
ment, Sparks, MD, USA) were used for susceptibility testing
against all the M. tb strains as described previously [18].
Solutions of all the test samples were prepared in DMSO
to obtain their respective concentrations. Previous results
for K. vesicatoria show an MIC of 50.00μg/mL against
H37Rv [4], and was tested here at three concentrations
(100.0, 50.00, and 25.00μg/mL) in triplicate. This extract
was also tested against two drug-resistant strains of M. tb
at the same concentrations. According to Lall et al. [12]
the chloroform root extract of E. natalensis has an MIC
of 8.00μg/mL against susceptible M. tb. This extract was
tested again at concentrations ranging from 16.00, 8.00 to
4.00μg/mL in triplicate. The EtOH extract of P. sidoides
exhibited an MIC above 5000μg/mL [19]a n dw a st e s t e d
at three concentrations (10000, 5000, and 2500μg/mL) in
triplicate. The hexane fraction (F2) and the tannin-free
fraction (F4) obtained from the tannin clean-up partitioning
were tested in triplicate at three concentrations (100.0, 50.00,
and 25.00μg/mL) based on the antimycobacterial activity
of these samples against M. smegmatis. Compounds (1)
and (2) were tested in triplicate at four concentrations4 Evidence-Based Complementary and Alternative Medicine
Figure 1: Undiﬀerentiated (A) and diﬀerentiated (B) U937 cells as viewed under a light microscope (100x magniﬁcation).
(200, 100, 50, and 25.00μg/mL). All the samples were
dissolvedin100%DMSOtoobtainstockconcentrationsthat
were subsequently serially diluted twofold to give the three
test concentrations. None of the samples exceeded a ﬁnal
DMSO concentration above 1.0% as control experiments
showed that a ﬁnal concentration of DMSO (1.0%) in the
medium had no adverse eﬀect on the growth of M. tb.
The primary drug INH (Sigma-Aldrich Chemical Co., South
Africa), at a concentration of 0.02mg/mL, served as the
drugcontrol in the bioassay.
2.6. Determining Synergistic Antimycobacterial Activity on
M. tuberculosis Using the BACTEC Radiometric Assay. The
activity of three diﬀerent drug, and extract combinations
was evaluated at sub-MIC levels (below original MIC values)
so that each component (extract or drug) was present
at concentrations corresponding to 1/2, 1/4, and 1/8o f
the MIC. Analysis of the drug combination data was
achieved by calculating the fractional inhibitory concen-
tration (FIC) index [20] with a general equation for use
with any number (n) of drugs in a combination as fol-
lows: FIC = (MICa combination/MICa alone)+( M I C b combination
+M I C b alone)+ ···+( M I C n combination +M I C n alone). The
subscripts represent the diﬀerent components in the drug
combination. The FIC was interpreted as follows: FIC ≤ 0.5,
synergistic activity; FIC = 1, indiﬀerence/additive activity;
FIC ≥ 2 or more, antagonistic activity [13, 21].
Three diﬀerent combinations of plant extracts and INH
were tested for possible synergistic activity against the drug
susceptible M. tb strain. Combination 1 (C1) included the
extracts of E. natalensis (CHCl3), K. vesicatoria (EtOH), and
P. sidoides (EtOH) in a four-drug combination with the ﬁrst-
line drug INH. Combination 2 (C2) only included the three
plant extracts in a three-drug combination. Combination
3 (C3) combined the K. vesicatoria (EtOH) extract and
INH in a two-drug combination. The BACTEC radiometric
method, as described before [13], was used to determine the
synergistic activity of these diﬀerent amalgamations.
2.7. Cytotoxicity. A l lr e a g e n t sw e r ep r o c u r e df r o mH i g h v e l d
Biological (Pty) (Ltd.) (Sandringham, South Africa) unless
indicated otherwise. The U937 cells were grown to a density
of 5 × 108 cells/mL, centrifuged, and washed with phosphate
buﬀeredsaline(PBS)solution.Theconcentrationofcellswas
adjusted to 1 × 105 cells/mL in complete medium containing
aﬁnalconcentrationof0.10μg/mLphorbol12-myristate13-
acetate (PMA) (Sigma-Aldrich Chemical Co., South Africa).
Two hundred microlitres of the cell suspension were seeded
into the inner wells of a 96-well tissue culture plate, while
the outer wells received 200.0μL of incomplete medium.
The cells were incubated for 24 hours at 37◦Ci na na t m o -
sphere of 5% CO2 to induce diﬀerentiation of monocytes
to mature macrophages (Figure 1)[ 22, 23]. Cytotoxicity
was measured by the 2,3-bis(2-methoxy-4-nitro-5-sulfoph-
enyl)-5-[(phenylamino)carbonyl]-2-H-tetrazolium hydrox-
ide (XTT) method using the Cell Proliferation Kit II (Roche
Diagnostics GmbH). Dilution series of E. natalensis, K.
vesicatoria (EtOH crude and tannin-free), and P. sidoides
extracts were prepared at various concentrations (400.0 to
3.125μg/mL). Synergistic combinations were tested at MIC
and sub-MIC levels to maintain the correct ratios of each
e x t r a c ta st e s t e da g a i n s tM. tb, accordingly each combination
was tested at diﬀerent starting concentrations. Combination
1wasmadeuptoacombinedconcentrationof5058.2μg/mL
in the ﬁrst well with a ﬁnal concentration of 39.52μg/mL.
Combination 2 was made up to a combined concentration
of 5058.0μg/mL in the ﬁrst well with a ﬁnal concentration
of 39.52μg/mL and C3 with concentrations ranging from
50.20 to 0.392μg/mL. The pure compounds (INH, (1) and
(2)) were made up to a stock concentration of 20.00mg/mL
and serially diluted to start with a concentration of 200.0 to
1.562μg/mL from the ﬁrst wells to the last in the microtitre
plates. The isomer mixture (compounds (2) and (3)) was
treated in the same way. These dilutions were added to
the inner wells of the microtiter plate and incubated for
72h. After 72h, 50.0μLo fX T Tr e a g e n t( 1 . 0 m g / m LX T T
with 0.383mg/mL PBS) was added to the wells and the
plates were then incubated for 1-2 hours. The positive
drug, (Actinomycin D, Sigma), at a ﬁnal concentration
range of 5.0 × 10−2 to 3.9 × 10−4 μg/mL, was included.
After incubation, the absorbance of the colour complex
was spectrophotometrically quantiﬁed using an ELISA plate
reader (PowerWave XS, Bio-Tek), which measures the ODEvidence-Based Complementary and Alternative Medicine 5
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Figure 2: Chemical structures of isolated compounds from Knowltonia vesicatoria.
at 450nm with a reference wavelength of 690nm. DMSO
(0.04%) was added to serve as the control for cell survival.
GraphPad Prism 4.03 software was used to statistically
analyse the 50% inhibitory concentration (IC50)v a l u e s .
3. Results andDiscussion
3.1. Identiﬁcation of the Isolated Compounds
Compound(1): Stigmasta-5,23-dien-3-ol. (Figure2)wasob-
tainedasclearcrystalsandwasidentiﬁedbasedonNMRdata
(1Ha n d13C) which were compared with those reported in
literature [24, 25].
Isomer mixture: 5-(hydroxymethyl)furan-2(5H)-one and
5-(hydroxymethyl)dihydrofuran-2(3H)-one. (Figure 2)w a s
obtained as a yellow oil. This sample is a ≈ 3:2 mixture
of compounds (2) and (3), respectively, as was revealed
by the integral of the 1H NMR spectrum and also by
the absence of HMBC and COSY correlations between the
signals corresponding to each one of the constituents.
Compound(2): 5-(hydroxymethyl)furan-2(5H)-one. (Fig-
ure 2)[ α]D-5.7(c 0.16, CHCl2); 1H NMR (500MHz,
CDCl3): δ 7.47 (1H, dd, J3,2 = 5.8Hz, J3,4 = 1.6Hz, H-3),
6.21 (1H, dd, J2,3 = 5.8Hz, J2,4 = 2.1Hz, H-2), 5.15 (1H,
dddd, J4,2 = 2.1Hz, J4,3 = 1.6Hz, J4,5A = 3.9Hz, J4,5B =
5.1Hz, H-4), 4.03 (1H, dd, J5A,5B = 12.2Hz, J5A,4 = 3.9Hz,
HA-5), 3.79 (1H, dd, J5A,5B = 12.2Hz, J5b,4 = 5.1Hz, HB-5).
The absolute stereochemistry at the C-4 asymmetric
centre not determined. Since (2) was obtained as a yellow
oily substance, the undeﬁned stereochemistry at the C-4
asymmetric centre is most likely the (S)- and not the
(R)-form as the latter crystallises and the (S)-form is an oil
[26].
3.2.MicrodilutionAssayUsingM.smegmatis. Althoughstud-
ies have shown that M. smegmatis c o u l db em o r er e s i s t a n tt o
drug activity than M. tuberculosis [27–29], screening samples
against nonpathogenic M. smegmatis gives quick results in
any laboratory ﬁtted for microbial tests and provides a good
indication of which samples will also be active against M.
tuberculosis. In most cases this strategy saves both time
and expensive reagents necessary to test numerous samples
against the pathogen, M. tb. In this case, the purpose of
screening the partitioned fractions was to promptly establish
if the tannin-free extract still exhibits the same activity
as the tannin-containing extract and whether the tannin-
concentrated fraction had higher antimycobacterial activity
than thewholeextract. Resultsclearly indicate that this is not
the case (Table 1).
The tannin-free extract (F4) exhibited an MIC four-
fold higher (2500μg/mL) than that of the crude tannin
containing EtOH extract (625.0μg/mL). This does not
automatically point to the conclusion that tannins are the
responsible components for Knowltonia’s antimycobacterial6 Evidence-Based Complementary and Alternative Medicine
Table 1: MIC and MBC values of the solvent-partitioned fractions against M. smegmatis compared to the crude EtOH extract of K.
vesicatoria.
Sample MICa (μg/mL) MBCb (μg/mL)
K. vesicatoria (EtOH) 625.0 1250
F1 2500 >2500
F2 (hexane layer) 1250 2500
F3 >2500 >2500
F4 (tannin-free) 2500 >2500
F5 >2500 >2500
DMSO% 12.50 12.50
Ciproﬂoxacin 1.250 1.250
aMinimum inhibitory concentration.
bMinimum bactericidal concentration.
activity. None of the partitioned fractions from K. vesicatoria
exhibited an MIC or MBC as low as that of the crude or
“whole” EtOH extract. Fraction 1, which still contained all of
the polyphenolic compounds but no nonpolar compounds,
had the same activity proﬁle as that of F4, with an MIC of
2500μg/mL and an MBC value of more than 2500μg/mL.
The fractions with concentrated levels of tannins, fractions
3 (containing mostly polyphenols) and 5 (existing mainly of
NaCl and polyphenol residue), had no activity at the highest
concentration tested (2500μg/mL) and were subsequently
not included for the M. tb antimycobacterial test. The
highest activity seen for the fractions was that of the
nonpolar compounds (F2) with an MIC and MBC of 1250
and 2500μg/mL, respectively. Fraction 2 and the tannin-
free fraction (F4) were tested against M. tb. The positive
drug control, ciproﬂoxacin, exhibited an MIC equal to its
MBC value of 1.250μg/mL, which is comparable to its
mycobactericidal value found in the literature [30]. The
highest percentage DMSO used for the samples in the assay
(2.50%) did not inhibit M. smegmatis growth as evident
with the MIC/MBC value of 12.50%. Taken as a whole,
the results imply that either the active compounds were
damaged during the partitioning procedure or that synergy
within the K. vesicatoria extract itself forms the basis of its
antimycobacterial activity.
3.3. Antitubercular Rapid Radiometric Assay Using M. tuber-
culosis. The antimycobacterial assays of the extracts against
M. tuberculosis using the BACTEC radiometric method
showed that K. vesicatoria inhibited M. tuberculosis at an
MIC of 50.0μg/mL. Pelargonium sidoides and E. natalensis
inhibited the bacteria at the 5000μg/mL and 8.00μg/mL
against M. tuberculosis (Table 2). These results correspond
very well with previous MIC values obtained for all of
the extracts [4, 11, 12, 18, 19]. The sensitive strain of
M. tb was not susceptible to either F2 (hexane layer) or
F4 (tannin-free extract) obtained from the K. vesicatoria
tannin clean-up procedure at the highest concentration
tested (100μg/mL). The antituberculosis positive drug, INH,
inhibited the growth of M. tuberculosis at 0.2μg/mL during
all the independent assays.
The combination drug action showed that only C1 and
C3 exhibited synergistic antimycobacterialactivity. Although
the combined MIC of C1 (E. natalensis (CHCl3)+K.
vesicatoria (EtOH) + P. sidoides (EtOH) + INH) was
reducedeightfoldfrom5058.2to632.30μg/mL,theFIC(0.5)
indicates that the combination had threshold synergistic
activity. This is mainly due to the high ratio of P. sidoides
(5000μg/mL equal to 98.8%) present in the combination.
The same situation, where the P. sidoides extract overwhelms
the other components in the amalgamation, is seen with
C2 (E. natalensis (CHCl3)+K. vesicatoria (EtOH) + P.
sidoides (EtOH)), which is slightly reﬂected by the FIC
(1.5), indicating an additive eﬀect of the combination. The
best synergistic result with an FIC of 0.25 was seen for
C3 (K. vesicatoria (EtOH) + INH) where the combined
MIC is reduced eightfold, from 50.20 to 6.275μg/mL. This
synergistic activity of C3 implies that if a patient were to
take INH prescribed for the treatment of TB and combined
this regime with the extract of K. vesicatoria, other possible
beneﬁts such as reduced length of INH treatment and
decreased toxicity due to lower intake concentrations of
K. vesicatoria could subsist. Testing the cytotoxicity of this
combination is the next step to shed some light on this
possibility.
The isomer mixture exhibited no inhibitory activity
against M. tb at the highest concentration tested (200.0μg/
mL). Since lactones are known to exhibit signiﬁcant
antibacterial properties, it was interesting to note that in this
case the sterol was considerably more active than the lactone
with an MIC of 50.00μg/mL compared to the lactone MIC
of 200.0μg/mL. It has been reported that phytosterols have
anti-inﬂammatory, antibacterial, antifungal, antiulcerative,
antioxidant,andantitumoralactivities[31,32].Additionally,
S a l u d e se ta l .[ 33] reported the antimycobacterial activity of
ﬁve phytosterols isolated from Morinda citrifolia against M.
tb. Three of these isolated sterols closely resemble the struc-
ture of stigmasta-5,23-dien-3-ol, with the only diﬀerences
being the position and degree of saturation. Stigmasta-4-en-
3-one and stigmasta-4,22-dien-3-one (used in combination)
hadanMIClowerthan2.00μg/mL;stigmasterolhadanMIC
of 32.00μg/mL. Another phytosterol saringosterol, isolatedEvidence-Based Complementary and Alternative Medicine 7
Table 2: Antimycobacterial activity against M. tuberculosis and cytotoxicity on U937 cells of test samples.
Samples MICa (μg/mL) FICb ΔGI4-3 ± SDc IC50 (μg/mL ± SD)d
V2e —— 2 2 .0 ±2.94 —
INH (0.2μg/mL) 0.20 — −2.50 ±2.12 >200.0
Actinomycin Df NTg —— 3 .820 ±0.258×10−3
K. vesicatoria EtOH 50.00h — −6.00 ±0.58 41.25 ±0.205
F4i >100.0 — 275.5 ±45.36 4 .77 ±1.812
F2j >100.0 — 288.5 ±65.1N T
E. natalensis CHCl3 8.000 — −3.50 ±0.88 12.22 ±0.025
P. sidoides EtOH 5000 — 20.00 ±1.85 43.54 ±0.465
Compound (1) 50.00 — −9.00 ±1.41 16.41 ±0.135
Compound (2) 100.0k —— 4 4 .70 ±0.50
Isomer mixture (2) and (3) >100.0 — 117.0 ±8.49 >200.0
C1 1.000/6.250/625.0/0.025l 0.50 −5.50 ±3.53 100.3 ±2.450
C2 4.000/25.00/2500m 1.50 17.00 ±5.65 108.6 ±0.89
C3 6.250/0.025n 0.25 −1.5 ±0.707 121.7 ±2.079
aMinimum inhibitory concentration.
bFractional inhibitory concentration index.
cΔGI value (mean ± standard deviation).
dFifty percent inhibitory concentration.
e10−2 inoculum control.
fCytotoxicity assay positive control.
gNot tested.
hMIC value for K. vesicatoria against both clinical drug-resistant M. tb strains: 4388 (resistant to INH and ETH; V2 ΔGI4-3 ± SD = 32.5 ± 4.95) and 5479
(resistant to INH, EMB, STR, RIF; V2 ΔGI3-2 ± SD = 34.5±0.71) was found to be 50.00μg/mL with ΔGI4-3 = 2.0±4.24 and ΔGI3-2 = 0.33±0.57, respectively.
iFraction 4: tannin-free Knowltonia fraction.
j Fraction 2: hexane Knowltonia fraction.
kBACTEC MIC not determined, MIC determined via microplate assay.
lEightfold reduction of respective MIC values for E. natalensis (CHCl3)+K. vesicatoria (EtOH) + P. sidoides (EtOH) + INH.
mTwofold reduction of respective MIC values for E. natalensis (CHCl3)+K. vesicatoria (EtOH) + P. sidoides (EtOH).
nEightfold reduction of respective MIC values for K. vesicatoria (EtOH) + INH.
fromLessonianigrescens,(abrownalgae)exhibitedextremely
low toxicity compared to its MIC of 0.250μg/mL [34].
Knowltonia vesicatoria inhibited both drug-resistant
strains of M. tuberculosis at an MIC of 50.0μg/mL (Table 2).
This activity indicates a mechanism of action diﬀerent to
INH, EMB, STR, and RIF. These drugs target cell wall
synthesis (INH, EMB), inhibit gene transcription (RIF), and
inhibit protein synthesis (STR) [35]. The antimycobacterial
mechanismofactionofK.vesicatoriahastobeinvestigatedin
ordertoconﬁrmthissuppositionasadiﬀerentmechanismof
actiontoINHcouldholdpositiveimplicationsonpreventing
drug resistance as well as targeting strains already resistant
to INH with the use of a drug therapy that combines K.
vesicatoria and INH.
3.4. Cytotoxicity. The XTT cytotoxicity assay is a rapid and
cost-eﬀective tool to help choose optimal candidates, those
samples with low cytotoxicity and high antimycobacterial
activity, similar to a therapeutic dose, and to exclude any
samples too toxic to test at their antimycobacterial concen-
tration for ensuing intracellular assays. The results obtained
(Table 2) indicated that the cytotoxicity eﬀects of the four
plant extracts on U937 cells demonstrated marginal toxicity
except for E. natalensis, which showed high toxicity at a
ﬁfty percent inhibitory concentration (IC50) of 12.22μg/mL
against the macrophages. The tannin-free extract of K.
vesicatoria (F4) had the highest IC0050 value (64.77μg/mL)
compared to the other plant extracts; the lowered toxicity is
most likely due to the lack of the protein binding polyphe-
nols. Knowltonia vesicatoria and P. sidoides showed similar
toxicity exhibiting IC50 values at 41.25 and 43.54μg/mL,
respectively (Table 2). With the synergistic combinations,
the approximate IC50 values for combinations 1 and 2 were
calculated as 100.3 and 108.6μg/mL, respectively. Synergistic
combination C3 had a resultant IC50 of 121.70μg/mL. The
toxicity proﬁles of the combinations were much better than
the individual extracts indicating a synergistic action on
lowering cytotoxicity.
The pure compounds, which included the antitubercular
drug INH and the cytotoxic drug Actinomycin D, showed
very diﬀerent cytotoxic proﬁles compared to the extracts
and combinations. With the compounds isolated from
K. vesicatoria, compound (1) was more than twofold as
toxic to the cells when compared to compound (2), with
an IC50 of 16.41 and 44.70μg/mL, respectively. The 3:2
isomer mixture of 5-(hydroxymethyl)furan-2(5H)-one (2)
and 5-(hydroxymethyl)dihydrofuran-2(3H)-one (3) was not
toxic to the macrophages even at the highest concentration
tested (200.0μg/mL) with more than 50 percent of the
cells still viable at this concentration. Isoniazid had a
similar eﬀect on the cells, with 80 percent of the cells still8 Evidence-Based Complementary and Alternative Medicine
viable at 200.0μg/mL, indicating an IC50 above this value.
Actinomycin D, which served as the positive control in the
cytotoxicity assay, exhibited an IC50 of 3.80 × 10−3μg/mL.
Similar to a therapeutic index, it is necessary to compare
the diﬀerence between cytotoxicity and antimycobacterial
activity of the tested samples in order to choose the best
candidates for possible treatment options. Of all the samples
INH had the broadest diﬀerence in toxicity when compared
tobiologicalactivity,followedbyC3,E.natalensis,theisomer
mixture and the EtOH extract of K. vesicatoria. Pelargonium
sidoides had the narrowest therapeutic range followed by F4,
C2, C1, and compounds (1) and (2).
4. Conclusion
This study adds to current literature by demonstrating the
synergistic antimycobacterial activity of the crude EtOH
extract from the aerial parts of K. vesicatoria in its entirety
and in a drug combination with the ﬁrst-line drug, isoniazid.
Based on these ﬁndings we assume that a drug combination
of INH with K. vesicatoria c o u l dh e l pp r e v e n ta n dc o m b a t -
resistant strains; however, further studies will have to be
carried out in order to demonstrate its eﬃcacy.
This paper is the ﬁrst to report on the isolation
of stigmasta-5, 23-dien-3-ol, and 5-(hydroxymethyl)furan-
2(5H)-one from K. vesicatoria; it is also the ﬁrst report of
the antimycobacterial activity of both these compounds.
Subsequentandongoingworkincludesinvestigatingthepos-
sible mechanism of action, intracellular antimycobacterial
activity, and measuring the immunomodulation of the most
active candidates.
The various aspects of the challenges faced in TB drug
discovery are applicable to other infectious agents. With
Knowltonia vesicatoria being reintroduced to the ﬁeld of
medicinal plant science, its extracts and isolated compounds
could also be applied to screening for activity against other
pathogens. It is the interplay of codeveloped methods on the
natural products chemical perspective that will improve the
chances of treatment success.
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